Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248711 · ClinicalTrials.gov registry record · NA
Project Movement/Daily Move Feasibility
A NA study, sponsored by Calm.com.
- Terminated
- Registry status
- NA
- Development phase
- 137
- Enrollment target
NCT05248711: Clinical Trial NA study, sponsored by Calm.com.
NCT05248711 is a NA study that was terminated before completion, run by Calm.com. The registered enrollment target is 137 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05248711, a NA study, was terminated before completion, sponsored by Calm.com.
- TERMINATED
- Registry status
- NA
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility (acceptability and demand) of the Daily Move in a diverse sample of US adults. Acceptability benchmarks: 214 participants recruited within three months (60% will identify as a racial/ethnic minority; 30% African American, 30% Hispanic); At least 70% of participants rate the intervention as satisfactory. Demand benchmarks: At least 70% of participants complete 75% of prescribed Daily Move sessions per week across the 8-weeks; Dropouts not to exceed \>30% of participants. Aim 2 - explore the pre-post trends in change of: Stress - Perceived Stress Scale (PSS), Anxiety and Depression - Hospital Anxiety and Depression Scale (HADS), Mindfulness- Mindful Attention Awareness Scale (MAAS), and Mood- Profile of Mood States (POMS).
Primary Outcome
Stress will be measured using the Perceived Stress Scale (PSS).
Interventions
- BEHAVIORAL Calm Daily Move
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2022-08-01 |
| Phase | NA |
Why NCT05248711 stopped before completion
NCT05248711 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Calm Daily Move is the first listed.
NCT05248711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05248711 about?
NCT05248711 is a clinical study titled "Project Movement/Daily Move Feasibility". The purpose of this study is to test the feasibility (acceptability and demand) of the Daily Move in a diverse sample of US adults. Acceptability benchmarks: 214 participants recruited within three months (60% will identify as a racial/ethnic minority; 30% African American, 30% Hispanic); At least 7...
What is the current status of trial NCT05248711?
This trial is currently terminated. It is a NA study. The enrollment target is 137 participants. The study started on 2022-01-06. Estimated completion is 2022-08-01.
What interventions are being tested in trial NCT05248711?
The interventions under investigation include: Calm Daily Move (BEHAVIORAL).
Who is sponsoring clinical trial NCT05248711?
This trial is sponsored by Calm.com, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05248711's enrollment target sits among peer trials
137 722nd of 2000 higher than 1,279 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI